You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

356 Results
Drug
Other Name(s): Lederle Leucovorin® (multiple brands available)
Apr 2019
Drug
Other Name(s): Sprycel®
Feb 2025
Drug
Other Name(s): Firmagon®
Feb 2025
Drug
Jun 2025
Drug
Other Name(s): Tykerb®
Sep 2025
Drug
Other Name(s): Lupron® , Lupron Depot® , Eligard®
May 2025
Drug
Other Name(s): CeeNU®
Aug 2024
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Lenvima®
Sep 2023
Drug
Other Name(s): Somatuline® Autogel®
Jun 2024
Drug
Other Name(s): Onivyde® (Baxalta Canada)
Sep 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025

Pages